The North America genetic testing market is estimated to record a CAGR of 10.43% during the forecast period, 2022-2030, reaching a revenue of $10970.7 million by 2030.

NORTH AMERICA GENETIC TESTING MARKET FORECAST 2022-2030

North America Genetic Testing Market by Type (Prenatal and Newborn Testing, Diagnostic Testing, Predictive & Pre symptomatic Testing, Carrier Testing, Pharmacogenomic Testing, Other Types) Market by Technology (Molecular Testing, Cytogenetic Testing, Biochemical Testing) Market by Application (Genetic Disease Diagnosis, Cancer Diagnosis, Cardiovascular Disease Diagnosis, Other Applications) Market by Disease (Cancer, Cystic Fibrosis, Huntington’s Disease, Sickle Cell Anaemia, Duchenne Muscular Dystrophy, Alzheimer’s Disease, Rare Diseases, Thalassemia, Other Diseases) by Geography

Request free sample

The North America genetic testing market is estimated to record a CAGR of 10.43% during the forecast period, 2022-2030, reaching a revenue of $10970.7 million by 2030.

The market growth is attributed to the early disease detection and prevention emphasis, the rising application of genetic testing in oncology, the increasing demand for personalized medicine, and a huge demand for direct-to-customer genetic tests. Also, there is a growing awareness about the benefits and the potentiality of genetic testing in diagnosing and curing abnormalities or diseases.

North America Genetic Testing Markets

To know more about this report, request a free sample copy

The North America genetic testing market growth evaluation includes the assessment of Canada and the United States. There is an increasing demand for personalized medicine in the region. Also, genetic testing is finding rising applications in oncology. Genetic testing enables the detection of several genetic disorders during pregnancy, using different non-invasive and invasive techniques. As a result, such technological developments help physicians perform tests with more precision and evaluate multiple genes at a time. Besides, there is a growing demand for effective and safe genetic tests. Such factors offer growth opportunities.

In the United States, most disabilities and deaths are attributed to chronic ailments like diabetes, heart disorders, and cancer, as per the Centers for Disease Control and Prevention (CDC). Also, the healthcare expenditure incurs $320 billion every year in indirect and direct costs. Accordingly, many healthcare companies are evaluating providing advanced screening solutions for disease detection at the preliminary stage and disease prevention. Besides, the surging awareness about the efficiency of genetic testing methods among healthcare professionals is favorable to market growth.

The North America genetic testing market scope includes the segmentation evaluation of technology, type, disease, and application. The disease segment is further sub-divided into cancer, Alzheimer’s disease, thalassemia, cystic fibrosis, Duchenne muscular dystrophy, Huntington’s disease, sickle cell anemia, rare diseases, and other diseases.

Cystic fibrosis and sickle cell anemia are evaluated to be the prominent disease categories contributing to market growth. Cystic fibrosis (CF) is an inherited disorder causing serious damage to the digestive system, lungs, and other organs. It affects cells that produce sweat, digestive juices, and mucus. These secreted fluids, usually slimy and thin, become thick and sticky in people with CF due to a defective gene. A genetic test and a sweat test are the two common tests used to diagnose CF. The former detects chromosomal mutations associated with the disease, while the latter measures chloride quantity in sweat.

Some of the eminent firms in the North America genetic testing market are Qiagen, Myriad Genetics Inc, PerkinElmer Inc, Luminex Corporation, etc.

Myriad Genetics Inc is a molecular diagnostic company that develops and markets prognostic, personalized, and predictive medicine tests. It offers sequencing tests for hereditary cancers. For instance, riskScore, a personalized medicine tool, and DNA sequencing test to evaluate the risk of developing ovarian and breast cancers. The company has a presence in 128 countries, with headquarters in Salt Lake City, Utah.

Further, the company has more product offerings in terms of genetic testing than its competitors. These include GeneSight, Prenatal, Prolaris, Vectra, Hereditary Cancer Testing, etc. GeneSight helps inform healthcare providers about the response and intensity of breakdown to certain mental health medications, thereby aiding in avoiding multiple medication trials.

Report Synopsis

Report Scope Details
Market Forecast Years 2022-2030
Base Year 2021
Market Historical Years 2018-2021
Forecast Units Revenue ($ Million)
Segments Analyzed Disease, Application, Technology, Type
Countries Analyzed United States and Canada
Companies Analyzed

23&Me Inc, Abbott Laboratories, BGI Group, Bio-Rad Laboratories, CSL Limited, Decode Genetics, ELITech Group, Eurofins Scientific, Illumina Inc, Luminex Corporation, Myriad Genetics Inc, PerkinElmer Inc, Qiagen, Quest Diagnostics Inc, and Roche Diagnostics Inc

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES
      • MARKET OVERVIEW
    3. MARKET DYNAMICS
      • KEY DRIVERS
        • ADVANCEMENTS IN BIOTECHNOLOGY
        • GROWTH IN PRENATAL TESTING
        • RISE IN DIRECT-TO-CONSUMER GENETIC TESTING
        • GENETIC TESTING HELPS IN DETERMINING MEDICATION DOSAGE
      • KEY RESTRAINTS
        • EXPENSIVE COST OF TREATMENT
        • GOVERNMENT REGULATION AND LEGISLATION
    1. KEY ANALYTICS
      • IMPACT OF COVID-19 ON GENETIC TESTING MARKET
      • KEY MARKET TRENDS
      • PORTER’S FIVE FORCES ANALYSIS
        • BUYERS POWER
        • SUPPLIERS POWER
        • SUBSTITUTION
        • NEW ENTRANTS
        • INDUSTRY RIVALRY
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
      • VALUE CHAIN ANALYSIS
      • KEY BUYING CRITERIA
      • REGULATORY FRAMEWORK
    2. MARKET BY TYPE
      • PRENATAL AND NEWBORN TESTING
      • DIAGNOSTIC TESTING
      • PREDICTIVE & PRESYMPTOMATIC TESTING
      • CARRIER TESTING
      • PHARMACOGENOMIC TESTING
      • OTHER TYPES
    3. MARKET BY TECHNOLOGY
      • MOLECULAR TESTING
      • CYTOGENETIC TESTING
      • BIOCHEMICAL TESTING
    4. MARKET BY APPLICATION
      • GENETIC DISEASE DIAGNOSIS
      • CANCER DIAGNOSIS
      • CARDIOVASCULAR DISEASE DIAGNOSIS
      • OTHER APPLICATIONS
    5. MARKET BY DISEASE
      • CANCER
      • CYSTIC FIBROSIS
      • HUNTINGTON’S DISEASE
      • SICKLE CELL ANAEMIA
      • DUCHENNE MUSCULAR DYSTROPHY
      • ALZHEIMER’S DISEASE
      • RARE DISEASES
      • THALASSEMIA
      • OTHER DISEASES
    6. GEOGRAPHICAL ANALYSIS
      • NORTH AMERICA
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        • COUNTRY ANALYSIS
          • UNITED STATES
          • CANADA
    1. COMPETITIVE LANDSCAPE
      • KEY STRATEGIC DEVELOPMENTS
        • MERGERS & ACQUISITIONS
        • PRODUCT LAUNCHES & DEVELOPMENTS
        • PARTNERSHIPS & AGREEMENTS
        • BUSINESS EXPANSIONS & DIVESTITURES
      • COMPANY PROFILES
        • 23&ME INC
        • ABBOTT LABORATORIES
        • BGI GROUP
        • BIO-RAD LABORATORIES
        • CSL LIMITED
        • DECODE GENETICS
        • ELITECH GROUP
        • EUROFINS SCIENTIFIC
        • ILLUMINA INC
        • LUMINEX CORPORATION
        • MYRIAD GENETICS INC
        • PERKINELMER INC
        • QIAGEN
        • QUEST DIAGNOSTICS INC
        • ROCHE DIAGNOSTICS INC

    LIST OF TABLES

    TABLE 1: MARKET SNAPSHOT – GENETIC TESTING

    TABLE 2: REGULATORY FRAMEWORK

    TABLE 3: NORTH AMERICA GENETIC TESTING MARKET, BY TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 4: NORTH AMERICA GENETIC TESTING MARKET, BY TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 5: NORTH AMERICA GENETIC TESTING MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 6: NORTH AMERICA GENETIC TESTING MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 7: NORTH AMERICA GENETIC TESTING MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 8: NORTH AMERICA GENETIC TESTING MARKET, BY APPLICATION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 9: NORTH AMERICA GENETIC TESTING MARKET, BY DISEASE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 10: NORTH AMERICA GENETIC TESTING MARKET, BY DISEASE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 11: NORTH AMERICA GENETIC TESTING MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 12: NORTH AMERICA GENETIC TESTING MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 13: LEADING PLAYERS OPERATING IN NORTH AMERICA GENETIC TESTING MARKET

    TABLE 14: LIST OF MERGERS & ACQUISITIONS

    TABLE 15: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

    TABLE 16: LIST OF PARTNERSHIPS & AGREEMENTS

    TABLE 17: LIST OF BUSINESS EXPANSIONS & DIVESTITURES                             

    LIST OF FIGURES

    FIGURE 1: KEY MARKET TRENDS

    FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

    FIGURE 3: OPPORTUNITY MATRIX

    FIGURE 4: VENDOR LANDSCAPE

    FIGURE 5: VALUE CHAIN ANALYSIS

    FIGURE 6: NORTH AMERICA GENETIC TESTING MARKET, GROWTH POTENTIAL, BY TYPE, IN 2021

    FIGURE 7: NORTH AMERICA GENETIC TESTING MARKET, BY PRENATAL AND NEWBORN TESTING GENETIC TESTING, 2022-2030 (IN $ MILLION)

    FIGURE 8: NORTH AMERICA GENETIC TESTING MARKET, BY DIAGNOSTIC TESTING, 2022-2030 (IN $ MILLION)

    FIGURE 9: NORTH AMERICA CARRIER TESTING MARKET, BY CARRIER TESTING, 2022-2030 (IN $ MILLION)

    FIGURE 10: NORTH AMERICA GENETIC TESTING MARKET, BY PHARMACOGENOMIC TESTING, 2022-2030 (IN $ MILLION)

    FIGURE 11: NORTH AMERICA GENETIC TESTING MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2021

    FIGURE 12: NORTH AMERICA GENETIC TESTING MARKET, BY MOLECULAR TESTING, 2022-2030 (IN $ MILLION)

    FIGURE 13: NORTH AMERICA GENETIC TESTING MARKET, BY CYTOGENETIC TESTING, 2022-2030 (IN $ MILLION)

    FIGURE 14: NORTH AMERICA GENETIC TESTING MARKET, BY BIOCHEMICAL TESTING, 2022-2030 (IN $ MILLION)

    FIGURE 15: NORTH AMERICA GENETIC TESTING MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2021

    FIGURE 16: NORTH AMERICA GENETIC TESTING MARKET, BY GENETIC DISEASE DIAGNOSIS, 2022-2030 (IN $ MILLION)

    FIGURE 17: NORTH AMERICA GENETIC TESTING MARKET, BY CANCER DIAGNOSIS, 2022-2030 (IN $ MILLION)

    FIGURE 18: NORTH AMERICA GENETIC TESTING MARKET, BY CARDIOVASCULAR DISEASES DIAGNOSIS, 2022-2030 (IN $ MILLION)

    FIGURE 19: NORTH AMERICA GENETIC TESTING MARKET, BY OTHER APPLICATIONS, 2022-2030 (IN $ MILLION)

    FIGURE 20: NORTH AMERICA GENETIC TESTING MARKET, GROWTH POTENTIAL, BY DISEASE, IN 2021

    FIGURE 21: NORTH AMERICA GENETIC TESTING MARKET, BY CANCER, 2022-2030 (IN $ MILLION)

    FIGURE 22: NORTH AMERICA GENETIC TESTING MARKET, BY CYSTIC FIBROSIS, 2022-2030 (IN $ MILLION)

    FIGURE 23: NORTH AMERICA GENETIC TESTING MARKET, BY HUNTINGTON’S DISEASE, 2022-2030 (IN $ MILLION)

    FIGURE 24: NORTH AMERICA GENETIC TESTING MARKET, SICKLE CELL ANEMIA, 2022-2030 (IN $ MILLION)

    FIGURE 25: NORTH AMERICA GENETIC TESTING MARKET, BY DUCHENNE MUSCULAR DYSTROPHY, 2022-2030 (IN $ MILLION)

    FIGURE 26: NORTH AMERICA GENETIC TESTING MARKET, BY ALZHEIMER’S DISEASE, 2022-2030 (IN $ MILLION)

    FIGURE 27: NORTH AMERICA GENETIC TESTING MARKET, BY RARE DISEASES, 2022-2030 (IN $ MILLION)

    FIGURE 28: NORTH AMERICA GENETIC TESTING MARKET, BY THALASSEMIA, 2022-2030 (IN $ MILLION)

    FIGURE 29: NORTH AMERICA GENETIC TESTING MARKET, BY OTHER DISEASES, 2022-2030 (IN $ MILLION)

    FIGURE 30: NORTH AMERICA GENETIC TESTING MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

    FIGURE 31: UNITED STATES GENETIC TESTING MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 32: CANADA GENETIC TESTING MARKET, 2022-2030 (IN $ MILLION)       

    1. GEOGRAPHICAL ANALYSIS
      • NORTH AMERICA
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        • COUNTRY ANALYSIS
          • UNITED STATES
          • CANADA
    1. MARKET BY TYPE
      • PRENATAL AND NEWBORN TESTING
      • DIAGNOSTIC TESTING
      • PREDICTIVE & PRESYMPTOMATIC TESTING
      • CARRIER TESTING
      • PHARMACOGENOMIC TESTING
      • OTHER TYPES
    2. MARKET BY TECHNOLOGY
      • MOLECULAR TESTING
      • CYTOGENETIC TESTING
      • BIOCHEMICAL TESTING
    3. MARKET BY APPLICATION
      • GENETIC DISEASE DIAGNOSIS
      • CANCER DIAGNOSIS
      • CARDIOVASCULAR DISEASE DIAGNOSIS
      • OTHER APPLICATIONS
    4. MARKET BY DISEASE
      • CANCER
      • CYSTIC FIBROSIS
      • HUNTINGTON’S DISEASE
      • SICKLE CELL ANAEMIA
      • DUCHENNE MUSCULAR DYSTROPHY
      • ALZHEIMER’S DISEASE
      • RARE DISEASES
      • THALASSEMIA
      • OTHER DISEASES

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type